Epeleuton

N/A

Report date: 2022/11/25 17:01:13
NME

Base Information

Drug NameEpeleuton
Drug Alias NameAF-102 - Afimmune5-hydroxyeicosapentaenoic acidDS-10215-HEPE
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionArachidonate 5-lipoxygenase inhibitors
TargetsArachidonate 5-lipoxygenase
Therapy Area/IndicationsHypertriglyceridemiaDiabetes Mellitus, Type 2Anemia, Sickle Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAfimmune Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAfimmune Ltd
Inactive CompaniesDs Biopharma Ltd
Active IndicationsAnemia, Sickle Cell
Inactive IndicationsHypertriglyceridemiaDiabetes Mellitus, Type 2Pulmonary Disease, Chronic Obstructive +[5] 

Other Information

ATC CodeN/A
Related LinksN/A